Investigación traslacional en patología infecciosa

Víctor Asensi Álvarez

• Catedratico de Universidad Vinculado de Medicina, Universidad de Oviedo
• Unidad de Enfermedades Infecciosas del Hospital Universitario Central de Asturias (HUCA)

• Patogénesis de la osteomielitis
• Patogénesis de la sepsis
• Infección por VIH y alteraciones metabólicas asociadas
• Inmunidad celular y humoral
• Tratamiento de las hepatitis B y C en coinfectados por VIH

• VALLE-GARAY, E.; MONTES, A.H.; CORTE, J.R.; MEANA, A.; FIERER, J.; ASENSI, V.: tPA Alu (I/D) polymorphism associates with bacterial Osteomyelitis. J Infect Dis 2013; 208: 218-223.
• SANTOS, DE LOS, I.; GÓMEZ-BERROCAL, A.; VALENCIA, E.; ASENSI, V.; GIJÓN, ; MORENO, V.; VERGAS, J.; BERNARDINO, I.: Efficacy and tolerability of darunavir/ritonavir in combination with abacavir/lamivudine. An option in selected HIV-infected patients. HIV Clin Trials 2013; 14: 254-260.
• GUTIÉRREZ, F.; GARCÍA, L.; PADILLA, S.; ÁLVAREZ, D.; MORENO, S.; NAVARRO, G.; GÓMEZ-SIRVENT, J.; VIDAL, F.; ASENSI, V.; MASIÁ, M.; CORIS: Risk of clinically significant depression in HIV-infected patients: effect of antiretroviral drugs. HIV Med 2014; 15:213-223.
• VILADÉS, C.; ESCOTÉ, X.; LÓPEZ-DUPLA, M.; MARTÍNEZ, E.; DOMINGO, P.; ASENSI, V.; LEAL, M.; PERAIRE, J.; INZA, M.I.; ARNEDO, M.; GUTIÉRREZ, M.; VALLE-GARAY, E.; FERRANDO-MARTÍNEZ, S.; OLONA, M.; ALBA, V.; SIRVENT, J.J.; GATELL, J.M.; VIDAL, F. on behalf of the HALS Study Group: Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS). J Antimicrob Chemother 2014; 69: 1653-1659.
• MARTÍNEZ-ZAPICO, A.; ASENSI, V.; FUENTES, N.; FONOLLA, M.; RODRÍGUEZ, M.; CÁRCABA, V.; CARTON, J.A.: Immune reconstitution inflammatory syndromeunmasking endophtalmic, lymphadenopathic, and neuromeningeal cryptococcosis in an HIV-infected patient starting highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2014; 30: 434-435.
• MARTÍN, G.; ASENSI, V.; MONTES, A.H.; COLLAZOS, J.; ÁLVAREZ, V.; CARTON, A.; TABOADA, F.; VALLE-GARAY, E.: Role of plasma matrixmetalloproteases (MMPs) and their polymorphisms (SNPs) in sepsis development and outcome in ICU patients. Sci Rep 2014; May 16; 4: 5002.
• PODZAMCZER, D.; IMAZ, A.; PÉREZ, I.; VICIANA, P.; VALENCIA, E.; CURTO, J.; MARTÍN, T.; CASTAÑO, M.; ROJAS, J.; ESPINOSA, N.; MORENO, V.; ASENSI, V.; IRIBARREN, J.A.; CLOTET, B.; FORCE, L.; BACHILLER, P.; KNOBEL, H.; LÓPEZ BERNALDO DE QUIRÓS, J.C.; BLANCO,J.R.; ROZAS, N.; VERGAS, J.; OCAMPO, A.; CAMACHO, A.; FLORES, J.; GÓMEZ-SIRVENT,J.L. on behalf of the KIDAR Study Group: Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antirretroviral therapy-naive and -experienced patients. J Antimicrob Chemother 2014;69: 2536-2540.
• PERAIRE, J.; LÓPEZ-DUPLA, M.; ALBA, V.; BELTRÁN-DEBON, R.; MARTÍNEZ, E.; DOMINGO, P.; ASENSI, V.; LEAL, M.; VILADÉS, C.; INZA, M.I.; ESCOTÉ, X.; ARNEDO, M.; MATEO, G.; VALLE-GARAY, E.; FERRANDO-MARTINEZ, S.; VELOSO, S.; VENDRELL, J.; GATELL, J.M.; HIV-1 LIPODYSTROPHY STUDY GROUP: HIV/antiretroviral therapy-related Lipodystrophy Syndrome (HALS) is associated with higher RBP4 and lower omentin in plasma. Clin Microbiol Infect 2015; 21: 711.e1-8.
• ECHEVARRÍA, A.; MORO-GARCÍA, M.A.; ASENSI, V.; CARTON, J.A.; LÓPEZLARREA,; ALONSO-ARIAS, R.: CD4 CD4+CD28null T lymphocytes resemble CD8+CD28null T lymphocytes in their responses to IL-15 and IL-21 in HIVinfected patients. J Leukoc Biol. 2015; 98: 373-284. COLLAZOS, J.; ASENSI, V.; MARTÍN, G.; MONTES, A.H; SUÁREZ-ZARRACINA, T; VALLE-GARAY, E.: The effect of gender and genetic polymorphisms on MMPs and TIMPs plasma levels in different infectious and non-infectious Clin Exp Immunol 2015; 182; 213-219.
• ASENSI, V.; COLLAZOS, J.; VALLE-GARAY, E.: ≪Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics. World J Virol 2015; 4: 169-177.
• ROJAS, C.; LONCA, M.; IMAZ, A.; ESTRADA, V.; ASENSI, V.; MIRALLES, C.; DOMINGO, P.; MONTERO, M.; DEL RÍO, L.; FONTDEVILA, J.; PÉREZ, L.; CRUCETA, A.; GATELL, J.M.; ARNEDO, M.; MARTÍNEZ, E.: Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir. HIV Med 2016; 17: 340-349.
• TORRECILLA GARCÍA,E.; YEBRA SANZ, G.; LLÁCER-DELICADO, T.; RUBIO GARCÏA, ; GONZÁLEZ-GARCÍA, J.; GARCÍA GARCÍA, F.; LÓPEZ-ALDEGUER, J.; ASENSI ÁLVAREZ, V.; HOLGUÍN FERNÁNDEZ, A.; COHORT OF THE SPANISH AIDS RESEARCH NETWORK (CORIS): Clinical, epidemiological and treatment failure data among HIV-1 non-B-infected patients in the Spanish AIDS Research Network cohort. Enf Infecc Microbiol Clin 2015; 33: 40.e1-40.e16.
• COLLAZOS, J.; VALLE-GARAY, E.; CARTON, J.A.; MONTES, A.H.; SUÁREZ ZARRACINA,; DE LA FUENTE, B.; ASENSI, V.: Factors associated with long-term CD4 cell recovery in HIV-infected patients under successful antiretroviral therapy. HIV Med 2016; 17: 532-541.
• SOBRINO-VEGAS, P.; MORENO, S.; RUBIO, R.; VICIANA, P.; BERNARDINO, J.I; BLANCO, J.R; BERNAL, E.; ASENSI, V.; PULIDO, F.; DEL AMO, J.; HERNANDO, V.; CORIS: Impact of late presentation of HIV infection on short-, midand long-term mortality and causes of death in a multicenter national cohort: 2004-2013≫. J Infect. 2016; 587-596.
• ALEJOS, B.; HERNANDO, V.; IRIBARREN; I.; GONZÁLEZ-GARCÍA, J.; HERNANDO,; SANTOS, J.; ASENSI, V.; GÓMEZ-BERROCAL, A.; DEL AMO, J.; JARRÍN, I.; CORIS (COHORT OF THE SPANISH NETWORK ON HIVAIDS RESEARCH). Overall and cause-specific excess mortality in HIV-positive persons compared with the general population: Role of HCV coinfection≫. Medicine (Baltimore). 2016; 95:e4727.
• Collazos J, Valle-Garay E, Suárez-Zarracina T, Montes AH, Cartón JA, Asensi V. Matrix metalloproteases and their tissue inhibitors in non-alcoholic liver fibrosis of human immunodeficiency virus-infected patients. World J Virol. 2017 May 12;6(2):36-45. doi: 10.5501/wjv.v6.i2.36.
• Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Palacios R, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GeSIDA 7011 Study Group.Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy (atazanavir/ritonavir + two nucleos(t)ides) in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). J Antimicrob Chemother. 2017 Jan;72(1):246-253.